Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus VISIPAQUE 320.
CONRAY 43 vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent